GC Biopharma KRX:006280KOSPI

녹십자 · Korean news coverage and regulatory filings, organized.

Articles, 24h42
Articles, 7 days71
DART filings, 7 days1
Articles tracked403since Sep 11

In Q2 2026, GC Biopharma reported revenue of ₩421bn, down 15.8% year on year, and operating profit of ₩1.7bn. GC Biopharma (녹십자) appeared in 71 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 30 with 37 articles. The most common catalyst was contracts & orders (24). It was most often mentioned alongside Hanmi Pharm, GC Cell and 글로벌테크놀로지.

GC Biopharma quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩421bn-15.8%₩1.7bn
margin 0.4%
₩1.1bn
Q1 2026₩436bn+13.5%₩11.7bn
margin 2.7%
₩20.1bn
Q4 2025 derived₩498bn+12.9%₩4.6bn
margin 0.9%
−₩103bn
Q3 2025₩609bn+31.1%₩29.2bn
margin 4.8%
₩18.1bn
Q2 2025₩500bn+19.9%₩27.4bn
margin 5.5%
₩32.7bn
Q1 2025₩384bn+7.6%₩8.0bn
margin 2.1%
₩22.3bn
Q4 2024 derived₩441bn+8.9%−₩10.1bn
margin −2.3%
−₩38.7bn
Q3 2024₩465bn+5.8%₩39.6bn
margin 8.5%
₩35.8bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

GC Biopharma top stories 2 weeks, by number of outlets

  1. 1
    GC녹십자의료재단·지씨셀·GC지놈, 진단검사 국제학술대회 공동 참여
    6 outlets · 6 articlesFirst report Oct 29 08:42 바이오타임즈GC Cell
  2. 2
    GC녹십자, 뇌실투여 헌터증후군 치료제 국내 허가
    5 outlets · 6 articlesFirst report Oct 30 10:04 메디파나뉴스
  3. 3
    녹십자·한미약품, 파브리병 신약 美 바이오마린에 최대 6300억원 기술수출
    5 outlets · 5 articlesFirst report Oct 30 06:02 이데일리Licensing dealHanmi Pharm
  4. 4
  5. 5
    GC녹십자·한미약품, 파브리병 신약 美 바이오텍 기술수출
    4 outlets · 4 articlesFirst report Oct 30 08:23 PRESS9Licensing dealHanmi Pharm
  6. 6
    한미약품·녹십자, 파브리병 치료제 美에 기술이전..6348억원 규모
    3 outlets · 3 articlesFirst report Oct 30 07:57 스마트투데이Licensing dealHanmi Pharm

Latest GC Biopharma news Korean headlines